{"id":"W2891585716","doi":"10.1200/jco.2017.35.15_suppl.tps5608","title":"Phase II open-label randomized multi-centre study of neoadjuvant olaparib in patients (pts) with platinum sensitive (PS) relapsed high grade serous ovarian cancer (OC): The NEO trial.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ozmosis Research (Canada); Université de Montréal; Princess Margaret Cancer Centre; Ottawa Hospital; Baker Hughes (Canada); University Health Network","funders":"","keywords":"Olaparib; Medicine; PARP inhibitor; Oncology; BRCA mutation; Internal medicine; Ovarian cancer; Clinical endpoint; Clinical trial; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001299379,0.001561003,0.002132232,0.0002404151,0.0003641796,0.001101367,0.000742831,0.00139041,0.008131921],"category_scores_gemma":[0.001240721,0.000672974,0.001087366,0.0003539947,0.00088041,0.0009979812,0.0005301246,0.002784095,0.001535503],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008338451,"about_ca_system_score_gemma":0.001330007,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007984267,"about_ca_topic_score_gemma":0.002377842,"domain_scores_codex":[0.9996748,0.0001744568,0.00001295783,0.00006105686,0.00002240946,0.00005429179],"domain_scores_gemma":[0.9992198,0.0001199009,0.000178203,0.00006341391,0.00003988827,0.0003787689],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9678949,0.0123272,0.001302753,0.0003912814,0.0003835957,0.0000725812,0.00006908034,0.0005576423,0.003571782,0.0001006307,0.001402262,0.01192634],"study_design_scores_gemma":[0.9171777,0.07820504,0.002488218,0.00002331846,0.0001358394,0.00007496793,0.00003071632,0.0003529316,0.0002510694,0.0002000564,0.001047915,0.00001228601],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.979555,0.001919288,0.0009445723,0.001224573,0.0003749896,0.009777054,0.003007736,0.0001325959,0.003064352],"genre_scores_gemma":[0.9686584,0.001970406,0.002245837,0.002131902,0.000297829,0.01532519,0.003423706,0.00004427259,0.005902514],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008131921,"threshold_uncertainty_score":0.02720398,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1887957207845303,"score_gpt":0.5059444769074753,"score_spread":0.317148756122945,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}